Loading
Crossignal Therapeutics develops small-molecule medicines meant to stop tumours hiding from the immune system. Its lead drug, CT3001, is in an early trial in advanced bowel, pancreatic and other solid cancers.
Crossignal Therapeutics, Inc., of La Jolla, California, develops small-molecule anti-cancer immunotherapies, using an assay platform it calls PPS to screen against difficult G-protein-coupled receptor targets. Its lead, CT3001, is described as a first-in-class small-molecule inhibitor of GPR35; company news links it to IDO1-mediated tumour immune escape through the Hippo-YAP pathway. CT3001 received FDA IND clearance in December 2023 and the company announced first-in-patient dosing in October 2024 in a phase 1/2 study (NCT06598007) of CT3001 alone and with FOLFOX, with a phase 2a part planned in advanced colorectal or pancreatic cancer. A second programme, CT3021, is a small-molecule antagonist of adenosine A2a, A2b and A1 receptors. Its first registered cancer trial, NCT06598007, was posted on ClinicalTrials.gov in September 2024.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/